THERMO FISHER SCIENTIFIC INC. (TMO) stock intrinsic value fair value estimate & owner earnings analysis

THE BUSINESS. Thermo Fisher Scientific is the largest supplier of tools, consumables and services to the life-sciences world. It sells analytical instruments (mass spectrometers, electron microscopes, chromatography), the reagents and consumables those instruments use, laboratory supplies through its Fisher distribution channel, specialty diagnostics, contract manufacturing of drugs (Patheon) and contract clinical research (PPD). Customers are pharmaceutical and biotech companies, universities and government labs, industrial users and hospitals. 2025 revenue was $44.6 billion: about 52% North America, 27% Europe, 18% Asia-Pacific. Organic revenue growth was 2% in 2025; pharma and biotech demand grew while academic and government demand and sales in China declined. EARNINGS LEVEL. We measure the cash the business produces for its owners: operating cash flow, minus stock-based pay, minus the capital spending needed to keep the business as it is (the ten-year average of about 3.8% of revenue; spending above that, tied to revenue growth, is treated as growth investment), with year-to-year swings in working capital set aside. On that basis owner earnings were $7.1 billion in 2023, $7.3 billion in 2024 and $7.8 billion in 2025 ($18.41, $19.06 and $20.67 per share). We look only at 2023-2025: the PPD acquisition at the end of 2021 changed the business, and 2020-2022 were inflated by pandemic testing and vaccine demand. Because the company carries a lot of debt, we value the business before its lenders and then subtract what it owes: adding back interest paid ($1.6 billion in 2025) and removing interest earned on cash (about $1.0 billion), the business produced $7.65 billion, $7.79 billion and $8.43 billion in 2023-2025. We anchor on the middle year, $7.79 billion, rather than 2025, because 2025 benefited from setting aside a $1.8 billion working-capital outflow that the company attributes mainly to the timing of income-tax payments. This level is dependable: pre-interest cash flow has run at roughly 18-20% of revenue in 2019 and in every year from 2022 to 2025, moving outside that band only during the pandemic boom. ACCOUNTING JUDGEMENTS. Amortization of acquired intangibles ($1.7-2.4 billion a year) is added back because it is a non-cash charge for past acquisitions. We do not treat those intangibles as wasting away, because the installed instruments, service contracts and products specified into regulated drug manufacturing keep generating repeat sales; the risk that they do not is carried in the bear case as a long period with no growth. Two acquisitions are paid for but not yet in the anchor year: Solventum's purification and filtration business (about $4.0 billion, closed September 2025) and Clario, a provider of clinical-trial endpoint data (about $8.9 billion, closed in the first half of 2026, with up to $525 million more in deferred and contingent payments). Their cost is in the debt below, so their earnings must be counted; the filings do not give their standalone cash flow, so we credit them with a cash return on the price paid of 5% in the base case (about $0.65 billion a year), 3.5% in the bear case and 6.5% in the bull case. Thermo Fisher's record of earning well on acquired businesses supports that range, but it is a judgement. GROWTH. In 2025 pre-interest cash flow grew 8.2% (owner earnings 7.0%). The base case assumes 3% a year for ten years, below last year's rate, credited only to pricing and repeat consumption of consumables by the installed base, both demonstrated through the pandemic boom and the 2023-2024 downturn. We give no credit for future acquisitions, because acquisitions cost cash that these figures do not deduct, and none for a rebound in academic funding or China. After year ten the base case holds cash flow flat rather than assuming growth: what keeps it going is the installed base and the cost to customers of requalifying suppliers in regulated drug production. BEAR CASE ($260 per share). The template is the industry's real downturn: from 2021 to 2023 this company's pre-interest cash flow fell 13.5% as customers worked down bioprocessing inventories and biotech funding dried up. The bear case repeats a downturn of that depth from today's base (for example a new biotech funding drought combined with deeper US academic funding cuts and further decline in China): cash flow 12% lower in year one and about 15% lower in year two, recovering to roughly today's level by year five and then never growing again. Acquisitions earn only 3.5% on their price, and debt is counted at full face value with the full contingent Clario payments. The business is worth about $136 billion ($366 per share); it owes about $39.0 billion net of cash ($105 per share), leaving about $260 per share. Even at the trough the business generates roughly $7.0 billion a year before interest against an interest bill of under $2 billion. BASE CASE ($382 per share). Anchor of $7.79 billion plus about $0.65 billion from the two recent acquisitions, growing 3% a year for ten years, then flat. The business is worth about $178 billion ($479 per share). Debt is about $42.5 billion at June 27, 2026 (up from $39.4 billion at the end of 2025 after funding Clario and $4.0 billion of share buybacks in the first half); much of it is long-dated, low-coupon bonds, and we count it at its reported fair value of $39.6 billion plus Clario deferred payments, less $4.1 billion of cash, for net debt of about $36.1 billion ($97 per share). Shareholders' value is about $382 per share. BULL CASE ($558 per share). Bioprocessing and pharma-services volumes recover and pricing holds: 6% growth a year for five years, 4% for the next five and 2.5% for a further decade before flattening, with the recent acquisitions earning 6.5% on their price. Business value about $243 billion ($655 per share) less the same $97 per share of net debt, about $558 per share. DEBT. The only financial covenant, in a $5 billion undrawn revolving credit facility, requires earnings before interest, taxes, depreciation and amortization of at least 3.5 times net interest; actual coverage is many times that. The company is a large, diversified, investment-grade borrower with laddered maturities, so refinancing is not a material risk in any case. MARGIN-OF-SAFETY PRICE ($250). We are fairly confident in the earnings level because it has held within a narrow band relative to revenue through a boom and a bust, and the company sells into thousands of customers across four segments with no controlling owner. The worst plausible outcome is a long funding drought for biotech and universities layered on drug-pricing or tariff policy that cuts pharma spending for several years; with debt of roughly five years of pre-interest cash flow and no near-term covenant pressure, the business would survive it. The things we are most likely to be wrong about are the earnings level, what Clario and Solventum actually earn, and whether any growth materializes; if the level is 10% lower, the acquisitions earn half what we assume and there is no growth at all, the shares are worth about $230. The price assumes a three-to-four-year holding period, during which the company returns cash through buybacks ($3.0 billion in 2025 and $4.0 billion in the first half of 2026) and a small dividend. From $250, the base case reached within about three years implies roughly a 20% annual return, the bear case implies a small gain, and only a combination of all three misjudgements implies a modest loss. That is why the margin-of-safety price is $250. CHANGES SINCE THE PREVIOUS ANALYSIS. The previous figures were prepared on a different basis and are not comparable. In the business itself, the Clario acquisition has closed and been financed with debt, first-half 2026 revenue rose 8.4% and operating income 11% over the first half of 2025, and buybacks have continued. WHAT COULD MAKE THIS WRONG. A downturn deeper or longer than 2023-2024; acquisitions that earn much less than their cost; or erosion of pricing power, for example from Chinese domestic suppliers or customers consolidating purchasing. Cash flow figures reconciled to reported net income in every year from 2016 to 2025 with no material gaps.